Dec. 7, 2018—Qiagen launched two novel products to deliver actionable insights on a wide range of blood cancers: a workflow for the Qiagen Clinical Insight Interpret bioinformatics solution for hematological malignancies, and the QIAact Myeloid DNA UMI Panel for use in myeloid neoplasm research using the company’s GeneReader NGS System.
The QIAact myeloid panel provides an integrated sample-to-insight workflow targeting the genes and variants most relevant to onco-hematology research. It is integrated with comprehensive bioinformatics for analysis and interpretation and covers 25 highly relevant genes and their variants, including single nucleotide variants and insertions/deletions of known significance to clonal myeloid malignancy. The panel became available for research use only in December 2018.
The new workflow for QCI Interpret was designed to consider the heterogeneous nature of myeloid malignancies and provides actionable information for the subclassification and prognostic assessment of hematological malignancies. QCI Interpret is a web-based clinical decision support platform that draws on the company’s Knowledge Base to evaluate genomic variants in the context of published biomedical literature, professional association guidelines, publicly and privately available databases, drug labels, and clinical trials. The software ranks data according to the highest level of evidence based on actionability tiers from the 2017 AMP/ASCO/CAP guidelines.